PRLHR

Across TCGA pan-cancer cohorts, PRLHR Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PRLHR data layer compared with 21 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PRLHR Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRLHR expression acts as an unfavorable survival marker.

LIHC, ESCA, and LUSC are the cancer types where PRLHR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	15	view →
ESCA	OS	Median	IV	0.095	0.512	.008	14	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	12	view →
COAD	OS	Median	IV	0.045	0.659	<.001	12	view →
KIRC	DFS	Median	All	0.152	0.865	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRLHR–LIHC (DFS)

Open the LIHC breakdown →